Alphamab (康宁杰瑞) Pre-IPO: Promising Readings from PHIP Updates
Alphamab obtained approval from HKSE last week and started pre-marketing for its USD 200-300m deal this week. In our previous notes, we covered the...
457 Views
Alphamab (康宁杰瑞) IPO: Thoughts on Base-Line Valuation
Alphamab, a China-based biotech company, is seeking to raise USD 200 to 300 million via a listing on the Hong Kong Stock Exchange. In our previous...
529 Views
Greater Bay Area Initiative - Viablity & Investor Implications, Part II
Last week in Part I we discussed what the GBA Initiative is. The importance of the GBA Initiative cannot be overstated. It is critical to the...
495 Views
Alphamab IPO: Interims from Merck's Breast Cancer Trial Bodes Well for Alphamab and Junshi
Last night, Merck & Co Inc. (MRK US) announced that its Keytruda hits primary endpoint in Phase III (KEYNOTE-522) clinical trial in the...
561 Views
🇨🇳🇭🇰 That Was The Week That Was • China/Hong Kong 22nd-27th July 2019 @Smartkarma
TW3 CHINA/HONG KONG 22-27 JUNEThis TW3 covers China and Hong Kong and is a companion to the North Asian TW3 published earlier today. The weight of...
567 Views